NCT02227147View on ClinicalTrials.gov

Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

September 30, 2016

Conditions
Neurotrophic Keratitis
Interventions
DRUG

rhNGF 20µg/ml

OTHER

Placebo

Formulation containing antioxidant

Trial Locations (12)

10003

New York Eye and Ear Infirmary, New York

15213

UPMC eye center, department of ophthalmology, University of Pittsburgh, Pittsburgh

19104

Penn Eye Care Scheie Eye Institute, Philadelphia

33324

Bascom Palmer Eye Institute University of Miami, Miami

55905

Mayo Clinic, Rochester

77030

Baylor College of Medicine, Houston

90095

Jules Stein Eye Institute, Los Angeles

92093

Shiley Eye Center University of California, San Diego

92354

Loma Linda University Ophthalmology, Loma Linda

02111

Tufts Medical Center, Boston

02114

Massachusetts Eye & Ear Infirmary, Boston

02451

Massachusetts Eye Research and Surgery Institution, Cambridge

All Listed Sponsors
lead

Dompé Farmaceutici S.p.A

INDUSTRY

NCT02227147 - Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK | Biotech Hunter | Biotech Hunter